Relmada Therapeutics Announces Oral Poster Presentation on REL-1017 at 2021 American Society of Clinical Psychopharmacology Annual Meeting
Relmada Therapeutics (Nasdaq: RLMD) announced that clinical data for REL-1017 will be presented at the 2021 ASCP Annual Meeting from June 1-4, 2021. The presentation, titled "REL-1017 is Safe, Well-Tolerated and Exerts Rapid, Robust and Sustained Antidepressant Effects", will feature insights from Marco Pappagallo, MD. REL-1017 aims to provide a rapid-acting, oral antidepressant treatment for major depressive disorder (MDD). The FDA granted Fast Track designation for REL-1017 in April 2017, confirming its promising safety and efficacy profile.
- Successful Phase 2 trial results for REL-1017, showing significant improvements over placebo.
- Fast Track designation from FDA for REL-1017 indicates potential for expedited development.
- Positive safety and tolerability profile confirmed in Phase 1 studies.
- None.
NEW YORK, May 26, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that clinical data related to REL-1017, the company's lead product candidate, will be presented in a live oral poster presentation at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, which is being held virtually between June 1 and June 4, 2021.
Details of the virtual oral presentation are as follows:
Title: REL-1017 (esmethadone) is Safe, Well-Tolerated and Exerts Rapid, Robust and Sustained Antidepressant Effects as Adjunctive Treatment in Patients with Major Depressive Disorder: a Phase 2 Double Blind Randomized Trial
Presenter: Marco Pappagallo, MD, Chief Medical Officer of Relmada Therapeutics
Session Title: Pharmaceutical Pipeline Session
Date and Time: Tuesday, June 1, 2021, from 2:45 – 4:45 PM ET
About REL-1017
REL-1017, a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is currently in late-stage development as an adjunctive treatment for MDD in adults. The ongoing RELIANCE Clinical Research Program is designed to evaluate the potential for REL-1017 as the first rapid-acting, oral, once-daily antidepressant treatment. In a Phase 2 trial, REL-1017 demonstrated rapid onset and sustained antidepressant effects with statistically significant improvements as compared to placebo. The Phase 2 study also confirmed the favorable safety and tolerability profile of REL-1017 observed in previously completed Phase 1 studies. In April 2017, the FDA granted Fast Track designation for REL-1017 for the adjunctive treatment of major depressive disorder.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Our experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive treatment for MDD in adults. Learn more at www.relmada.com.
Forward-Looking Statements
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding the expected use of the proceeds from the offering. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to," "potential," "promising," and similar expressions. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including the risk factors described under the heading "Risk Factors" set forth in the Company's reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be a complete list.
Investor Contact:
Tim McCarthy
LifeSci Advisors
212-915-2564
tim@lifesciadvisors.com
Media Inquiries:
FischTank PR
relmada@fischtankpr.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/relmada-therapeutics-announces-oral-poster-presentation-on-rel-1017-at-2021-american-society-of-clinical-psychopharmacology-annual-meeting-301299806.html
SOURCE Relmada Therapeutics, Inc.
FAQ
What is the significance of the REL-1017 presentation at the ASCP Annual Meeting?
When will Relmada Therapeutics present data on REL-1017?
What were the results of the Phase 2 trial for REL-1017?
What is REL-1017 and how does it work?
What designation did the FDA grant REL-1017?
